NeuroVision Imaging

NeuroVision is an integrated neuroscience company focused on delivering scientifically validated, diagnostic tests & biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s Disease. The company has developed a novel retinal imaging technology, which is currently being utilized in a number of clinical trials globally.With access to unique datasets, we provide data aggregation services, analysis, biostatistics, and applications of machine learning algorithms to large repositories of images and other biomarker data seeking to advance the collective understanding and prediction capabilities for neurodegenerative diseases.

NeuroVision Imaging headquartered in United States, North America, operates in the Biotechnology, Machine Learning, Health Care, Neuroscience, Health Diagnostics sector. The company focuses on Biotechnology and has secured $2.1B in funding across 100 round(s). With a team of 1-10 employees, NeuroVision Imaging is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - NeuroVision Imaging, raised $10.0M. Discover more about their projects, partnerships, and impact on our platform.